Cargando…

HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB

BACKGROUND: Eradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the persistence of long-lived latently infected resting memory CD4(+) T cells. We previously reported that HIV latency could be established in resting CD4(+) T cells in the presence of the che...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Suha, Lu, Hao K., Evans, Vanessa, Harisson, David, Zhou, Jingling, Jaworowski, Anthony, Sallmann, Georgina, Cheong, Karey Y., Mota, Talia M., Tennakoon, Surekha, Angelovich, Thomas A., Anderson, Jenny, Harman, Andrew, Cunningham, Anthony, Gray, Lachlan, Churchill, Melissa, Mak, Johnson, Drummer, Heidi, Vatakis, Dimitrios N., Lewin, Sharon R., Cameron, Paul U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962537/
https://www.ncbi.nlm.nih.gov/pubmed/27459960
http://dx.doi.org/10.1186/s12977-016-0284-7
_version_ 1782444855642816512
author Saleh, Suha
Lu, Hao K.
Evans, Vanessa
Harisson, David
Zhou, Jingling
Jaworowski, Anthony
Sallmann, Georgina
Cheong, Karey Y.
Mota, Talia M.
Tennakoon, Surekha
Angelovich, Thomas A.
Anderson, Jenny
Harman, Andrew
Cunningham, Anthony
Gray, Lachlan
Churchill, Melissa
Mak, Johnson
Drummer, Heidi
Vatakis, Dimitrios N.
Lewin, Sharon R.
Cameron, Paul U.
author_facet Saleh, Suha
Lu, Hao K.
Evans, Vanessa
Harisson, David
Zhou, Jingling
Jaworowski, Anthony
Sallmann, Georgina
Cheong, Karey Y.
Mota, Talia M.
Tennakoon, Surekha
Angelovich, Thomas A.
Anderson, Jenny
Harman, Andrew
Cunningham, Anthony
Gray, Lachlan
Churchill, Melissa
Mak, Johnson
Drummer, Heidi
Vatakis, Dimitrios N.
Lewin, Sharon R.
Cameron, Paul U.
author_sort Saleh, Suha
collection PubMed
description BACKGROUND: Eradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the persistence of long-lived latently infected resting memory CD4(+) T cells. We previously reported that HIV latency could be established in resting CD4(+) T cells in the presence of the chemokine CCL19. To define how CCL19 facilitated the establishment of latent HIV infection, the role of chemokine receptor signalling was explored. RESULTS: In resting CD4(+) T cells, CCL19 induced phosphorylation of RAC-alpha serine/threonine-protein kinase (Akt), nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinase (ERK) and p38. Inhibition of the phosphoinositol-3-kinase (PI3K) and Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK)/ERK signalling pathways inhibited HIV integration, without significant reduction in HIV nuclear entry (measured by Alu-LTR and 2-LTR circle qPCR respectively). Inhibiting activation of MEK1/ERK1/2, c-Jun N-terminal kinase (JNK), activating protein-1 (AP-1) and NF-κB, but not p38, also inhibited HIV integration. We also show that HIV integrases interact with Pin1 in CCL19-treated CD4(+) T cells and inhibition of JNK markedly reduced this interaction, suggesting that CCL19 treatment provided sufficient signals to protect HIV integrase from degradation via the proteasome pathway. Infection of CCL19-treated resting CD4(+) T cells with mutant strains of HIV, lacking NF-κB binding sites in the HIV long terminal repeat (LTR) compared to infection with wild type virus, led to a significant reduction in integration by up to 40-fold (range 1–115.4, p = 0.03). This was in contrast to only a modest reduction of 5-fold (range 1.7–11, p > 0.05) in fully activated CD4(+) T cells infected with the same mutants. Finally, we demonstrated significant differences in integration sites following HIV infection of unactivated, CCL19-treated, and fully activated CD4(+) T cells. CONCLUSIONS: HIV integration in CCL19-treated resting CD4(+) T cells depends on NF-κB signalling and increases the stability of HIV integrase, which allow subsequent integration and establishment of latency. These findings have implications for strategies needed to prevent the establishment, and potentially reverse, latent infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-016-0284-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4962537
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49625372016-07-28 HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB Saleh, Suha Lu, Hao K. Evans, Vanessa Harisson, David Zhou, Jingling Jaworowski, Anthony Sallmann, Georgina Cheong, Karey Y. Mota, Talia M. Tennakoon, Surekha Angelovich, Thomas A. Anderson, Jenny Harman, Andrew Cunningham, Anthony Gray, Lachlan Churchill, Melissa Mak, Johnson Drummer, Heidi Vatakis, Dimitrios N. Lewin, Sharon R. Cameron, Paul U. Retrovirology Research BACKGROUND: Eradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the persistence of long-lived latently infected resting memory CD4(+) T cells. We previously reported that HIV latency could be established in resting CD4(+) T cells in the presence of the chemokine CCL19. To define how CCL19 facilitated the establishment of latent HIV infection, the role of chemokine receptor signalling was explored. RESULTS: In resting CD4(+) T cells, CCL19 induced phosphorylation of RAC-alpha serine/threonine-protein kinase (Akt), nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinase (ERK) and p38. Inhibition of the phosphoinositol-3-kinase (PI3K) and Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK)/ERK signalling pathways inhibited HIV integration, without significant reduction in HIV nuclear entry (measured by Alu-LTR and 2-LTR circle qPCR respectively). Inhibiting activation of MEK1/ERK1/2, c-Jun N-terminal kinase (JNK), activating protein-1 (AP-1) and NF-κB, but not p38, also inhibited HIV integration. We also show that HIV integrases interact with Pin1 in CCL19-treated CD4(+) T cells and inhibition of JNK markedly reduced this interaction, suggesting that CCL19 treatment provided sufficient signals to protect HIV integrase from degradation via the proteasome pathway. Infection of CCL19-treated resting CD4(+) T cells with mutant strains of HIV, lacking NF-κB binding sites in the HIV long terminal repeat (LTR) compared to infection with wild type virus, led to a significant reduction in integration by up to 40-fold (range 1–115.4, p = 0.03). This was in contrast to only a modest reduction of 5-fold (range 1.7–11, p > 0.05) in fully activated CD4(+) T cells infected with the same mutants. Finally, we demonstrated significant differences in integration sites following HIV infection of unactivated, CCL19-treated, and fully activated CD4(+) T cells. CONCLUSIONS: HIV integration in CCL19-treated resting CD4(+) T cells depends on NF-κB signalling and increases the stability of HIV integrase, which allow subsequent integration and establishment of latency. These findings have implications for strategies needed to prevent the establishment, and potentially reverse, latent infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-016-0284-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4962537/ /pubmed/27459960 http://dx.doi.org/10.1186/s12977-016-0284-7 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Saleh, Suha
Lu, Hao K.
Evans, Vanessa
Harisson, David
Zhou, Jingling
Jaworowski, Anthony
Sallmann, Georgina
Cheong, Karey Y.
Mota, Talia M.
Tennakoon, Surekha
Angelovich, Thomas A.
Anderson, Jenny
Harman, Andrew
Cunningham, Anthony
Gray, Lachlan
Churchill, Melissa
Mak, Johnson
Drummer, Heidi
Vatakis, Dimitrios N.
Lewin, Sharon R.
Cameron, Paul U.
HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title_full HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title_fullStr HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title_full_unstemmed HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title_short HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB
title_sort hiv integration and the establishment of latency in ccl19-treated resting cd4(+) t cells require activation of nf-κb
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962537/
https://www.ncbi.nlm.nih.gov/pubmed/27459960
http://dx.doi.org/10.1186/s12977-016-0284-7
work_keys_str_mv AT salehsuha hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT luhaok hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT evansvanessa hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT harissondavid hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT zhoujingling hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT jaworowskianthony hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT sallmanngeorgina hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT cheongkareyy hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT motataliam hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT tennakoonsurekha hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT angelovichthomasa hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT andersonjenny hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT harmanandrew hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT cunninghamanthony hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT graylachlan hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT churchillmelissa hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT makjohnson hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT drummerheidi hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT vatakisdimitriosn hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT lewinsharonr hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb
AT cameronpaulu hivintegrationandtheestablishmentoflatencyinccl19treatedrestingcd4tcellsrequireactivationofnfkb